Table of Contents Author Guidelines Submit a Manuscript

Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia

Call for Papers

Alzheimer's disease (AD) and Lewy body disorders (LBDs) are the two most important reasons for neurodegenerative dementia syndromes. Due to an aging population and other demographic changes, prevalence of these neurodegenerative diseases is steadily increasing. This leads to growing social and economic burden. Basically only symptomatic treatments for these disorders are presently available. However, intensive research in these fields gives reasonable hope for neuromodulatory, neuroprotective and disease-modifying therapies to become soon a reality. The evaluation of such therapies is, however, heavily dependent on existence of reliable diagnostic and prognostic biomarkers for early detection and evaluation of the stages of the disease, defining the rate of disease progression prior to and following existing and future therapeutic interventions. Current biomarkers of these devastating neurodegenerative diseases are not sufficient for these purposes as the neurodegenerative processes start long before appearance of clinical symptoms. Candidate biomarkers for a preclinical diagnosis are strongly required. Hence, there is an urgent need for development, characterization, and improvement of such new and hopefully multifaceted biomarkers. For this special issue, we invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to develop and improve all kinds of biomarkers for these two neurodegenerative diseases. We are particularly interested in articles describing new methodological approaches and new hypothesis which would stimulate biomarker approaches in AD and LBD. However, studies investigating the validity of the existing biomarkers or combinations of them are also welcome. Potential topics include, but are not limited to:

  • Recent developments in neurochemical biomarkers
  • Recent developments in imaging biomarkers
  • Recent developments in genetic markers
  • Recent developments in multimodal approaches

Before submission authors should carefully read over the journal's Author Guidelines, which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:

Manuscript DueFriday, 8 June 2012
First Round of ReviewsFriday, 31 August 2012
Publication DateFriday, 28 October 2012

Lead Guest Editor

  • Thomas Leyhe, Department of Psychiatry and Psychotherapy, University Hospital of Tübingen, Calwer Straße 14, 72076 Tübingen, Germany

Guest Editors

  • Taher Darreh-Shori, Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Novum 4th Floor, 141 86 Stockholm, Sweden
  • Christoph Laske, Department of Psychiatry and Psychotherapy, University Hospital of Tübingen, Calwer Straße 14, 72076 Tübingen, Germany
  • Walter Maetzler, Center of Neurology, Hertie Institute of Clinical Brain Research, University Hospital of Tübingen, Hoppe-Seiler-Straße 3, 727076 Tübingen; Germany
  • Michelle M. Mielke, Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA